SCHEMBL10180438

SCHEMBL10180438

O=C(O)c1cc(I)cc(I)c1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.45
ALDH1A1 P00352 4/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAOB P27338 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP6 P55212 1/20 0.38
DTYMK P23919 1/20 0.38
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.36
GPR35 Q9HC97 1/20 0.35
TSHR P16473 1/20 0.35
CDK2 P24941 1/20 0.35
PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10180003 0.80 SMN1; SMN2 (0.42) PKMALDH1A1TDP1HTTMEN1
SCHEMBL10179802 0.76 CRHBP (0.41) PKMALDH1A1CYP1A2CYP2C19HTT
SCHEMBL10179559 0.76 ALDH1A1 (0.46) ALDH1A1MEN1LMNAKMT2AMAPT
SCHEMBL310877 0.76 TSHR (0.51) PKMALDH1A1TDP1CYP3A4ALOX15
SCHEMBL11799475 0.73 CASP6 (0.48) PKMALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL23499792 0.73 CA1 (0.49) ALDH1A1CYP1A2TDP1CYP3A4ALOX15
SCHEMBL1354508 0.72 PKM (0.50) PKMALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL11310440 0.72 PKM (0.50) PKMALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL11316296 0.72 PKM (0.50) PKMALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL2896179 0.71 DTYMK (0.46) ALDH1A1CYP1A2CYP2D6CYP2C19TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102574814-B The preparation method of pyrimidyl acetonitrile derivative and synthetic intermediate thereof IHARA CHEMICAL INDUSTRY CO.,LTD. (JP) 2015-09-16 CN disclosed
EP-2474536-B1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF IHARA CHEMICAL IND CO (JP) 2014-06-25 EP disclosed
US-20120178931-A1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF IHARA CHEMICAL INDUSTRY CO., LTD (JP) 2012-07-12 US disclosed
EP-2474536-A1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF Ihara Chemical Industry Co., Ltd. (JP) 2012-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178931-A1 PROCESS FOR PREPARATION OF PYRIMIDINYLACETONITRILE DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF DPYD, UMPS, PNP PKM 549/4885ALDH1A1 238/4885CYP1A2 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.